Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.

Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A.

Target Oncol. 2018 Apr;13(2):217-226. doi: 10.1007/s11523-017-0548-8.

2.

[THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].

Belilovski Rozenblum A, Ilouze M, Dudnik E, Soussan-Gutman L, Dvir A, Peled N.

Harefuah. 2017 Nov;156(11):686-691. Hebrew.

PMID:
29198084
3.

Quantification of specific T and B cells immunological markers in children with chronic and transient ITP.

Levy-Mendelovich S, Lev A, Aviner S, Rosenberg N, Kaplinsky C, Sharon N, Miskin H, Dvir A, Kenet G, Schushan IE, Somech R.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26646. Epub 2017 May 22.

PMID:
28544224
4.

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y.

J Thorac Oncol. 2017 Jul;12(7):e81-e84. doi: 10.1016/j.jtho.2017.02.023. Epub 2017 Mar 7. No abstract available.

5.

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.

Sarfaty M, Moore A, Neiman V, Dudnik E, Ilouze M, Gottfried M, Katznelson R, Nechushtan H, Sorotsky HG, Paz K, Katz A, Saute M, Wolner M, Moskovitz M, Miller V, Elvin J, Lipson D, Ali S, Gutman LS, Dvir A, Gordon N, Peled N.

Clin Lung Cancer. 2017 Jul;18(4):e223-e232. doi: 10.1016/j.cllc.2016.09.003. Epub 2016 Oct 29.

PMID:
28082048
6.

A novel swine model of ricin-induced acute respiratory distress syndrome.

Katalan S, Falach R, Rosner A, Goldvaser M, Brosh-Nissimov T, Dvir A, Mizrachi A, Goren O, Cohen B, Gal Y, Sapoznikov A, Ehrlich S, Sabo T, Kronman C.

Dis Model Mech. 2017 Feb 1;10(2):173-183. doi: 10.1242/dmm.027847. Epub 2017 Jan 6.

7.

Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.

Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.

J Thorac Oncol. 2017 Feb;12(2):258-268. doi: 10.1016/j.jtho.2016.10.021. Epub 2016 Nov 16.

8.

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.

Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, Yust-Katz S, Lokiec A, Ram Z, Ross JS, Ali SM, Yair R, Soussan-Gutman L, Bokstein F.

J Neurooncol. 2016 Oct;130(1):211-219. Epub 2016 Aug 16.

PMID:
27531351
9.

152P: The clinical utility of next-generation sequencing in lung cancer.

Rozenblum AB, Ilouze M, Dudnik E, Flex D, Dvir A, Soussan-Gutman L, Peled N.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S124. doi: 10.1016/S1556-0864(16)30262-3. Epub 2016 Apr 15. No abstract available.

10.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.

Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki J, Elvin JA, Wollner M, Dvir A, -Gutman LS, Bordoni R, Peled N, Braiteh F, Raez L, Erlich R, Ou SH, Mohamed M, Ross JS, Stephens PJ, Ali SM, Miller VA.

Clin Cancer Res. 2016 Jul 1;22(13):3281-5. doi: 10.1158/1078-0432.CCR-15-1668. Epub 2016 Mar 1.

11.

Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.

Yablonski-Peretz T, Paluch-Shimon S, Gutman LS, Kaplan Y, Dvir A, Barnes-Kedar I, Kadouri L, Semenisty V, Efrat N, Neiman V, Glasser Y, Michaelson-Cohen R, Katz L, Kaufman B, Golan T, Reish O, Hubert A, Safra T, Yaron Y, Friedman E.

Breast Cancer Res Treat. 2016 Jan;155(1):133-8. doi: 10.1007/s10549-015-3662-2. Epub 2015 Dec 19.

PMID:
26687385
12.

Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy.

Popovtzer A, Sarfaty M, Limon D, Marshack G, Perlow E, Dvir A, Soussan-Gutman L, Stemmer SM.

Biomed Res Int. 2015;2015:614845. doi: 10.1155/2015/614845. Epub 2015 Sep 13.

13.

Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.

Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R.

Biomed Res Int. 2015;2015:681653. doi: 10.1155/2015/681653. Epub 2015 May 28.

14.

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N.

Oncologist. 2015 Mar;20(3):316-22. doi: 10.1634/theoncologist.2014-0389. Epub 2015 Feb 26.

15.

Low-level constitutional mosaicism of a de novoBRCA1 gene mutation.

Friedman E, Efrat N, Soussan-Gutman L, Dvir A, Kaplan Y, Ekstein T, Nykamp K, Powers M, Rabideau M, Sorenson J, Topper S.

Br J Cancer. 2015 Feb 17;112(4):765-8. doi: 10.1038/bjc.2015.14. Epub 2015 Jan 29.

16.

Hormone dependent metastatic salivary gland carcinoma: a case report.

Agbarya A, Billan S, Nasrallah H, Dvir A, Soussan-Gutman L, Kaidar-Person O.

Springerplus. 2014 Jul 16;3:363. doi: 10.1186/2193-1801-3-363. eCollection 2014.

17.

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA.

Clin Cancer Res. 2014 Apr 1;20(7):1757-1767. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.

18.

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I.

Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.

19.

Naturally occurring mastitis disrupts developmental competence of bovine oocytes.

Roth Z, Dvir A, Kalo D, Lavon Y, Krifucks O, Wolfenson D, Leitner G.

J Dairy Sci. 2013 Oct;96(10):6499-505. doi: 10.3168/jds.2013-6903. Epub 2013 Aug 16.

PMID:
23957998
20.

Efficient production of recombinant human transcription factor IIE.

Moon WJ, Apostol JA, McBride AJ, Shukla LI, Dvir A, Burton ZF.

Protein Expr Purif. 2004 Apr;34(2):317-23.

PMID:
15003267
21.

Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model.

Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, Harats D.

Eur J Intern Med. 2003 Dec;14(8):479-483.

PMID:
14962699
22.

Assays for investigating the mechanism of promoter escape by RNA polymerase II.

Dvir A, Conaway JW, Conaway RC.

Methods Enzymol. 2003;370:733-40. No abstract available.

PMID:
14712687
23.

Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.

Levy Z, Dvir A, Shaish A, Trestman S, Cohen H, Levkovietz H, Rhachmani R, Ravid M, Harats D.

Int J Exp Diabesity Res. 2003 Jan-Mar;4(1):59-64.

24.

Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.

Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, Cohen H, Dvir A, Rhachmani R, Ravid M, Harats D.

Diabetes Obes Metab. 2003 Jan;5(1):45-50.

PMID:
12542724
25.

Promoter escape by RNA polymerase II. Downstream promoter DNA is required during multiple steps of early transcription.

Wang X, Spangler L, Dvir A.

J Biol Chem. 2003 Mar 21;278(12):10250-6. Epub 2003 Jan 13.

26.

Promoter escape by RNA polymerase II.

Dvir A.

Biochim Biophys Acta. 2002 Sep 13;1577(2):208-223. Review.

PMID:
12213653
27.

Brachial plexus injury and obstetrical risk factors.

Bar J, Dvir A, Hod M, Orvieto R, Merlob P, Neri A.

Int J Gynaecol Obstet. 2001 Apr;73(1):21-5.

PMID:
11336717
28.

TFIIH action in transcription initiation and promoter escape requires distinct regions of downstream promoter DNA.

Spangler L, Wang X, Conaway JW, Conaway RC, Dvir A.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5544-9. Epub 2001 May 1.

29.

Mechanism of transcription initiation and promoter escape by RNA polymerase II.

Dvir A, Conaway JW, Conaway RC.

Curr Opin Genet Dev. 2001 Apr;11(2):209-14. Review.

PMID:
11250146
30.

Control of elongation by RNA polymerase II.

Conaway JW, Shilatifard A, Dvir A, Conaway RC.

Trends Biochem Sci. 2000 Aug;25(8):375-80. Review.

PMID:
10916156
31.

Mechanism of promoter escape by RNA polymerase II.

Conaway JW, Dvir A, Moreland RJ, Yan Q, Elmendorf BJ, Tan S, Conaway RC.

Cold Spring Harb Symp Quant Biol. 1998;63:357-64. No abstract available.

PMID:
10384300
33.

A role for TFIIH in controlling the activity of early RNA polymerase II elongation complexes.

Dvir A, Conaway RC, Conaway JW.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9006-10.

34.

Assays for investigating transcription by RNA polymerase II in vitro.

Reines D, Dvir A, Conaway JW, Conaway RC.

Methods. 1997 Jul;12(3):192-202. Review.

PMID:
9237163
35.
36.

A role for ATP and TFIIH in activation of the RNA polymerase II preinitiation complex prior to transcription initiation.

Dvir A, Garrett KP, Chalut C, Egly JM, Conaway JW, Conaway RC.

J Biol Chem. 1996 Mar 29;271(13):7245-8.

37.

Stimulation of the DNA-dependent protein kinase by RNA polymerase II transcriptional activator proteins.

Peterson SR, Jesch SA, Chamberlin TN, Dvir A, Rabindran SK, Wu C, Dynan WS.

J Biol Chem. 1995 Jan 20;270(3):1449-54.

38.

Bile and plasma lipid composition in non-obese normolipidemic subjects with and without cholesterol gallstones.

Halpern Z, Rubin M, Harach G, Grotto I, Moser A, Dvir A, Lichtenberg D, Gilat T.

Liver. 1993 Oct;13(5):246-52.

PMID:
8259036
39.

Purification and characterization of a template-associated protein kinase that phosphorylates RNA polymerase II.

Dvir A, Stein LY, Calore BL, Dynan WS.

J Biol Chem. 1993 May 15;268(14):10440-7.

40.

Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II.

Dvir A, Peterson SR, Knuth MW, Lu H, Dynan WS.

Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11920-4.

41.

Effect of lipid infusion on bile composition and lithogenicity in patients without cholesterol gall stones.

Rubin M, Halpern Z, Charach G, Dvir A, Antebi E, Gilat T, Lichtenberg D.

Gut. 1992 Oct;33(10):1400-3.

42.

DNA binding provides a signal for phosphorylation of the RNA polymerase II heptapeptide repeats.

Peterson SR, Dvir A, Anderson CW, Dynan WS.

Genes Dev. 1992 Mar;6(3):426-38.

43.

The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers.

Dvir A, Milner Y, Chomsky O, Gilon C, Gazit A, Levitzki A.

J Cell Biol. 1991 May;113(4):857-65.

44.

The identification and purification of a mammalian-like protein kinase C in the yeast Saccharomyces cerevisiae.

Simon AJ, Milner Y, Saville SP, Dvir A, Mochly-Rosen D, Orr E.

Proc Biol Sci. 1991 Feb 22;243(1307):165-71.

PMID:
1676520
45.

[Israel national childhood acute lymphoblastic leukemia study].

Stark B, Abramov A, Attias D, Balin A, Burstein Y, Barak Y, Jaber L, Goshen Y, Dvir A, Hagai E, et al.

Harefuah. 1990 Apr 1;118(7):373-82. Hebrew.

PMID:
2351344
46.

Biologic and cytogenetic characteristics of leukemia in infants.

Stark B, Vogel R, Cohen IJ, Umiel T, Mammon Z, Rechavi G, Kaplinsky C, Potaznik D, Dvir A, Yaniv Y, et al.

Cancer. 1989 Jan 1;63(1):117-25.

PMID:
2910409
47.

Heterogeneity of childhood acute lymphoblastic leukemia (ALL): monoclonal antibodies phenotyping and induction of differentiation in vitro.

Umiel T, Luria D, Stark B, Cohen IJ, Gozes Y, Kobiler D, Kodman Y, Grunspan A, Dvir A, Yaniv I, et al.

Leukemia. 1988 Dec;2(12 Suppl):88S-96S.

PMID:
3264367
48.

[Testicular involvement in childhood leukemia].

Kaplinsky C, Alpert G, Cohen I, Dvir A, Zaizov R.

Harefuah. 1986 May 1;110(9):431-3. Hebrew. No abstract available.

PMID:
3463528
49.

Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child.

Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL, Zaizov R.

Cancer. 1983 Jan 1;51(1):9-14.

PMID:
6571794

Supplemental Content

Support Center